Compare Adaptive Biotechnologies Corp (ADPT) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Monolithic Power Systems Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Monolithic Power Systems Inc trades at $1,320.96 (market cap $62.53B). The key difference: Monolithic Power Systems Inc is far larger — about 18.8× Adaptive Biotechnologies Corp's market cap, and Monolithic Power Systems Inc pays a 0.63% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MPWR | |
|---|---|---|
Market Cap | $3.33B | $62.53B |
Sector | Health | Utilities |
52-Week High | $22.37 | $1.69K |
52-Week Low | $10.24 | $711.24 |
Enterprise Value | $3.19B | $61.19B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MPWR trades at $1,346.13, up 4.5% in the past 24 hours, showing strong momentum. The stock exhibits bearish technical signals but benefits from consistent earnings beats and robust profitability, with a net margin of 22.98%. Recent news highlights growth in AI infrastructure and consumer electronics demand. Cash flow remains positive, and a $2.00 dividend is scheduled for July 2026.
Outlook is supported by analyst optimism (88% buy ratings) and a consensus price target of $1,760, though high valuation multiples and ongoing legal investigations pose risks. Revenue growth and AI-driven demand present opportunities, but investors should weigh elevated P/E of 96.36 against potential market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
